Fixing The UK Market: Government Must Move From ‘Transactional’ To ‘Strategic’ Approach
BGMA Chair Diane DiGangi Trench Explains Why A Fresh Relationship With Industry Is Needed
With the UK market experiencing approval delays, shortages, and regulatory complexity, the government’s “policy vacuum” and complacent approach to off-patent medicines risk undermining the sector, says BGMA chair Diane DiGangi Trench. In an exclusive interview with Generics Bulletin, she urges a shift from a “transactional” to a “strategic” relationship with industry to fully unlock the benefits of generics and biosimilars.
